Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 10M | 6M | 6M | 7M |
| Gross Profit | 7M | 7M | 4M | 5M | 6M |
| Operating Income | -10M | -62M | -2M | -2M | 252K |
| EBITDA | -9M | -3M | -2M | 0 | 0 |
| Net Income | -15M | -58M | -4M | -836K | 476K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0584
+0.00% today
1Y Change
+60.44%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 203 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VSee Health, Inc. (VSEEW) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.06 and up 60.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +40.3%, EPS growth of +87.1%, a dividend yield of 0.0%. What stands out right now is revenue +40.3%, EPS +87.1%, free cash flow +40.5% with operating margin -65.6% and ROIC -119.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VSEEW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VSEEW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VSEEW Max Drawdown
-84.78%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VSEEW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.3M
+15.0% YoY
FY Net Income
$475.9K
+156.9% YoY
Free Cash Flow
-$600.1K
+58.7% YoY
Revenue Growth
+40.3%
EPS Growth
+87.1%
Gross Margin
50.3%
Net Margin
-100.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 15M | 10M | 6M | 6M | 7M |
| Gross Profit | 7M | 7M | 4M | 5M | 6M |
| Operating Income | -10M | -62M | -2M | -2M | 252K |
| EBITDA | -9M | -3M | -2M | 0 | 0 |
| Net Income | -15M | -58M | -4M | -836K | 476K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 326K | 119K | 231K | 760K |
| Total Assets | 22M | 20M | 806K | 3M | 118M |
| Total Liabilities | 17M | 20M | 5M | 3M | 5M |
| Shareholder Equity | 5M | -18K | -4M | 361K | 113M |
| Total Debt | 2M | 10M | 543K | 517K | 0 |
| Net Debt | -3M | 9M | 424K | 286K | -760K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
600K
+58.7% YoY
Capital Expenditures
3
+0.0% YoY
Free Cash Flow
600K
+58.7% YoY
Key ratios
Gross Margin
50.3%
Operating Margin
-65.6%
Net Margin
-100.6%
ROE
629.0%
Debt / Equity
0.45x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.